Childhood Hepatocellular Carcinoma - 9 Studies Found Recruiting : Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery : Advanced Adult Hepatocellular Carcinoma Localized Non-Resectable Adult Hepatocellular Carcin : 2014-02-24 : Other: Laboratory Biomarker Analysis Active, not recruiting : Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery : Adult Cholangiocarcinoma Advanced Adult Hepatocellular Carcinoma Drug: Capecitabine Given PO Completed : Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer : Childhood Hepatocellular Carcinoma Papillary Thyroid Cancer : 2011-12-29 : Drug: sorafenib tosylate Given Withdrawn : Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer : Liver Cancer : 2009-05-09 : Genetic: comparative genomic hybridization Withdrawn : Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery : Liver Cancer : 2007-05-08 : Biological: recombinant interferon alfa-2b Withdrawn : Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer : Liver Cancer : 2006-01-12 : Drug: cisplatin Drug: cyclophosphamide Completed : Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor : Cancer : 2005-09-08 : Biological: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/k Completed : Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases : Colorectal Cancer Islet Cell Tumor Liver Cancer : 2001-07-11 : Drug: isolated perfusion Drug: melphalan Completed : Chemotherapy in Treating Children With Liver Cancer : Liver Cancer : 1999-11-01 : Drug: carboplatin Drug: cisplatin
